Clinical Trials Browser

Phase 2 × zimberelimab × 30 days × Clear all

NCT05130177 2026-03-31

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Phase 2 Active not recruiting

Melanoma

NCT04736173 2026-03-30

ARC-10

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05329766 2026-03-30

EDGE-Gastric

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT07397611 2026-03-20

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Phase 2 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms